Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06339177 · ClinicalTrials.gov registry record
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
A clinical trial of Macrophage Activation Syndrome and Lymphohistiocytosis, Hemophagocytic, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 300
- Enrollment target
- 2
- Study locations
NCT06339177 is a study of Macrophage Activation Syndrome and Lymphohistiocytosis, Hemophagocytic that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 300 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06339177, a study of Macrophage Activation Syndrome and Lymphohistiocytosis, Hemophagocytic, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a nongenetic form (sHLH). They also do not have good ways to diagnose and treat sHLH. Objective: To learn about sHLH and why some people get it and others do not. Eligibility: Adults aged 18 years and older with sHLH. Design: Participants will be admitted to the study based on a review of their medical records. Those who join will have at least 3 clinical evaluations over 9 to 12 months. These may occur during an inpatient hospitalization if they require medical care or in the outpatient clinic. Participants will also have a physical exam at each visit. Up to half a cup of blood will be drawn at each visit. Participants may also have their blood drawn by their own doctors, who will send the samples to the researchers. Researchers may also contact these participants by telephone or video calls. The blood will be used for clinical tests as well as research. No new treatments will be administered as part of this study; however, standard medications and treatments may be recommended. Participants may opt to continue their visits once a year for 3 more years. Participants may also opt for an extra clinial evaluation 1 week after starting a new treatment. ...
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2031-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06339177
The ClinicalTrials.gov registry entry for NCT06339177 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Macrophage Activation Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT06339177 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06339177 about?
NCT06339177 is a clinical study titled "Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study". Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a ...
What is the current status of trial NCT06339177?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-07-02. Estimated completion is 2031-04-01.
What conditions does trial NCT06339177 study?
This clinical trial studies the following conditions: Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Hyperinflammatory Syndromes.
Who is sponsoring clinical trial NCT06339177?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06339177 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macrophage Activation Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Macrophage Activation Syndrome
All registered trials for this condition
Lymphohistiocytosis, Hemophagocytic
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.